BCG vaccine

The Bacillus Calmette–Guérin (BCG) vaccine is a live attenuated vaccine primarily used to prevent tuberculosis (TB), prepared from a strain of the attenuated live bovine tuberculosis bacillus, Mycobacterium bovis.

History and Development

The vaccine is named after its inventors, Albert Calmette and Camille Guérin, who were French bacteriologists working at the Pasteur Institute. Between 1908 and 1921, they cultured a virulent strain of Mycobacterium bovis on a glycerin-bile-potato mixture, subculturing it 230 times until it lost its virulence in animal models. The first human administration of the BCG vaccine occurred in 1921 in Paris. Despite early controversies, such as the Lübeck disaster in 1930 where contaminated batches caused infant deaths, the vaccine's safety and efficacy were subsequently validated, leading to its widespread global adoption.

Medical Uses

The primary indication for the BCG vaccine is the prevention of tuberculosis. It is particularly effective in preventing severe, disseminated forms of the disease in infants and young children, such as tuberculous meningitis and miliary tuberculosis.

Beyond tuberculosis, the BCG vaccine is a standard immunotherapy for early-stage, non-muscle-invasive bladder cancer. Administered directly into the bladder via a catheter (intravesical therapy), it stimulates a localized immune response that destroys cancer cells and significantly reduces the risk of tumor recurrence. Additionally, the vaccine has shown some cross-protective efficacy against other mycobacterial infections, including leprosy and Buruli ulcer.

Mechanism of Action

As a live attenuated vaccine, BCG contains viable Mycobacterium bovis bacteria that have lost their ability to cause disease in healthy individuals but retain their immunogenicity. Upon administration, the bacilli are phagocytosed by local antigen-presenting cells, such as macrophages and dendritic cells. This triggers a robust cell-mediated immune response, characterized by the activation of T-helper 1 (Th1) cells and the production of cytokines like interferon-gamma (IFN-γ). This immune priming enables the body to mount a rapid and effective defense if subsequently exposed to virulent Mycobacterium tuberculosis.

Administration and Dosage

The BCG vaccine is typically administered via a strict intradermal injection, usually on the deltoid region of the upper arm. In countries with a high burden of tuberculosis, the World Health Organization (WHO) recommends a single dose at birth or as soon as possible thereafter. In regions with lower TB incidence, vaccination may be targeted at high-risk populations or administered later in childhood. A successful intradermal injection typically produces a small wheal at the injection site, which eventually ulcerates, heals, and leaves a characteristic permanent scar known as the BCG scar.

Efficacy and Limitations

The efficacy of the BCG vaccine varies significantly depending on the geographical region, the age of the recipient, and the specific strain of the vaccine used. It provides excellent protection against severe childhood forms of TB. However, its efficacy against pulmonary tuberculosis in adults is highly variable, ranging from 0% to 80% in different clinical trials. This variable protection in adults is a major limitation, as pulmonary TB is the most common and transmissible form of the disease. Furthermore, BCG vaccination can cause false-positive results on the tuberculin skin test (Mantoux test), complicating the screening for latent TB infection, although interferon-gamma release assays (IGRAs) are not affected by prior BCG vaccination.

Adverse Effects and Contraindications

The BCG vaccine is generally safe, with the most common adverse effects being localized reactions. These include pain, erythema, and induration at the injection site, followed by ulceration and scar formation. Regional lymphadenitis may also occur. Severe complications, such as disseminated BCG infection (BCGosis) or osteomyelitis, are exceedingly rare but can be life-threatening.

Because it is a live bacterial vaccine, BCG is strictly contraindicated in individuals with compromised immune systems, including those with congenital immunodeficiencies, symptomatic HIV infection, or those receiving immunosuppressive therapy. It is also generally contraindicated during pregnancy due to the theoretical risk of fetal infection.

Global Usage and Policies

The BCG vaccine is one of the most widely used vaccines in the world and is included in the World Health Organization's List of Essential Medicines. Over 150 countries include it in their national immunization programs, administering it to more than 100 million children annually. While universal neonatal vaccination is the standard in TB-endemic regions, countries with low TB prevalence, such as the United States and the United Kingdom, employ targeted vaccination strategies, reserving the vaccine for individuals at high risk of exposure, such as healthcare workers or immigrants from high-burden countries. Ongoing research continues to explore novel TB vaccines to overcome the limitations of the current BCG strain.